Login to Your Account



FDA mulls next steps on commonly used MRI contrast agents

By Mari Serebrov
Regulatory Editor

Thursday, September 7, 2017

Erring on the side of caution, the FDA may take its education efforts up a notch by requiring a new label warning for gadolinium-based contrast agents (GBCAs) commonly used in MRIs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription